Actinium Pharmaceuticals Inc. (Delaware) (ATNM) Fundamentals

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
SHARE INFORMATION
Market Cap$ 135,571,684
Shares Outstanding23,784,506
Float23,776,536
Percent Float99.97%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 1,144,000
Latest Fiscal EPS$ -1.20
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions68
Institutional Holdings Date2022-07-31
Institutional Bought Previous 3 Months225,350
Institutional Holdings Percent18.4%
Institutional Sold Previous 3 Months79,430
Insider Holdings Date2022-07-31
Insider Bought Previous 3 Months1,444,584
Insider Holdings Percent1.8
Insider Sold Previous 3 Months-
Insider Shares Owned428,848
TRADING INFO
52 Week High$ 10.30
52 Week Low$ 4.41
52 Week High Change$ -12.17
21 Day Moving Average$ 5.1414
21 Day Extended Moving Average$ 5.2558
50 Day Moving Average$ 5.135
50 Day Extended Moving Average$ 5.2471
200 Day Moving Average$ 5.8475
200 Day Extended Moving Average$ 5.8565
10 Day Average Volume100,567
20 Day Average Volume96,519
30 Day Average Volume97,854
50 Day Average Volume124,090
Alpha-0.003587
Beta0.4020
Standard Deviation0.224704
R20.008005
7 Day Price Change$ 0.13
7 Day Percent Change2.33%
21 Day Price Change$ 0.60
21 Day Percent Change11.76%
30 Day Price Change$ 0.67
30 Day Percent Change13.32%
Month to Date Price Change$ 0.77
Month to Date Percent Change15.62%
Quarter to Date Price Change$ 0.89
Quarter to Date Percent Change18.5%
180 Day Price Change$ 0.64
180 Day Percent Change12.65%
200 Day Price Change$ 0.35
200 Day Percent Change6.54%
Year to Date Price Change$ -0.31
Year to Date Percent Change-5.16%

Actinium Pharmaceuticals Inc. (Delaware) (ATNM) Key Ratios

PROFITABILITY
EBIT Margin-1,693.3%
EBITDA Margin-1,656.6%
Pre-Tax Profit Margin0.0%
Profit Margin Count0.0%
Gross Margin0.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 1,196,000
Revenue Per Share$ 0.0503
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book2.00
Total Debt To Equity0.00
Int Coverage0.00
Current Ratio12.90
Leverage Ratio1.10
Quick Ratio12.60
Long Term Debt To Capital0.00
VALUATION MEASURES
PE Ratio-5.00
Enterprise Value$ 62,560,458
Price to Sales113.3543
Price to Free Cash-8.10
PE High Last 5 Years-2.10
Price To Book2.00
Price To Cash Flow0.00
PE Low Last 5 Years-2.70
Price to Tangible Book2.00
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.00
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-33.80
Return on Equity-36.25
Return on Capital-35.26

Actinium Pharmaceuticals Inc. (Delaware) (ATNM) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorMarcum LLP
CEOSandesh Seth
Emplyoees32
Last AuditUQ
CIK0001388320
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address275 Madison Avenue
7th Floor
New York, NY 10016
Websitehttps://www.actiniumpharma.com
Facsimile+1 845 818-3588
Telephone+1 646 677-3870
Emailinvestorrelations@actiniumpharma.com


Your Recent History
AMEX
ATNM
Actinium P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.